194 related articles for article (PubMed ID: 22676470)
1. Polyclonal HER2-specific antibodies induced by vaccination mediate receptor internalization and degradation in tumor cells.
Ren XR; Wei J; Lei G; Wang J; Lu J; Xia W; Spector N; Barak LS; Clay TM; Osada T; Hamilton E; Blackwell K; Hobeika AC; Morse MA; Lyerly HK; Chen W
Breast Cancer Res; 2012 Jun; 14(3):R89. PubMed ID: 22676470
[TBL] [Abstract][Full Text] [Related]
2. Synergism from combined immunologic and pharmacologic inhibition of HER2 in vivo.
Morse MA; Wei J; Hartman Z; Xia W; Ren XR; Lei G; Barry WT; Osada T; Hobeika AC; Peplinski S; Jiang H; Devi GR; Chen W; Spector N; Amalfitano A; Lyerly HK; Clay TM
Int J Cancer; 2010 Jun; 126(12):2893-903. PubMed ID: 19856307
[TBL] [Abstract][Full Text] [Related]
3. Polyfunctional anti-human epidermal growth factor receptor 3 (anti-HER3) antibodies induced by HER3 vaccines have multiple mechanisms of antitumor activity against therapy resistant and triple negative breast cancers.
Osada T; Hartman ZC; Wei J; Lei G; Hobeika AC; Gwin WR; Diniz MA; Spector N; Clay TM; Chen W; Morse MA; Lyerly HK
Breast Cancer Res; 2018 Aug; 20(1):90. PubMed ID: 30092835
[TBL] [Abstract][Full Text] [Related]
4. Cytokeratin19 induced by HER2/ERK binds and stabilizes HER2 on cell membranes.
Ju JH; Oh S; Lee KM; Yang W; Nam KS; Moon HG; Noh DY; Kim CG; Park G; Park JB; Lee T; Arteaga CL; Shin I
Cell Death Differ; 2015 Apr; 22(4):665-76. PubMed ID: 25342465
[TBL] [Abstract][Full Text] [Related]
5. Endogenous anti-HER2 antibodies block HER2 phosphorylation and signaling through extracellular signal-regulated kinase.
Montgomery RB; Makary E; Schiffman K; Goodell V; Disis ML
Cancer Res; 2005 Jan; 65(2):650-6. PubMed ID: 15695410
[TBL] [Abstract][Full Text] [Related]
6. An adenoviral vaccine encoding full-length inactivated human Her2 exhibits potent immunogenicty and enhanced therapeutic efficacy without oncogenicity.
Hartman ZC; Wei J; Osada T; Glass O; Lei G; Yang XY; Peplinski S; Kim DW; Xia W; Spector N; Marks J; Barry W; Hobeika A; Devi G; Amalfitano A; Morse MA; Lyerly HK; Clay TM
Clin Cancer Res; 2010 Mar; 16(5):1466-77. PubMed ID: 20179231
[TBL] [Abstract][Full Text] [Related]
7. Vaccine-Induced Memory CD8
Crosby EJ; Gwin W; Blackwell K; Marcom PK; Chang S; Maecker HT; Broadwater G; Hyslop T; Kim S; Rogatko A; Lubkov V; Snyder JC; Osada T; Hobeika AC; Morse MA; Lyerly HK; Hartman ZC
Clin Cancer Res; 2019 May; 25(9):2725-2736. PubMed ID: 30635338
[TBL] [Abstract][Full Text] [Related]
8. Disulfide bond disrupting agents activate the unfolded protein response in EGFR- and HER2-positive breast tumor cells.
Ferreira RB; Wang M; Law ME; Davis BJ; Bartley AN; Higgins PJ; Kilberg MS; Santostefano KE; Terada N; Heldermon CD; Castellano RK; Law BK
Oncotarget; 2017 Apr; 8(17):28971-28989. PubMed ID: 28423644
[TBL] [Abstract][Full Text] [Related]
9. Novel anti-HER2 monoclonal antibodies: synergy and antagonism with tumor necrosis factor-α.
Ceran C; Cokol M; Cingoz S; Tasan I; Ozturk M; Yagci T
BMC Cancer; 2012 Oct; 12():450. PubMed ID: 23033967
[TBL] [Abstract][Full Text] [Related]
10. Heterologous human/rat HER2-specific exosome-targeted T cell vaccine stimulates potent humoral and CTL responses leading to enhanced circumvention of HER2 tolerance in double transgenic HLA-A2/HER2 mice.
Xie Y; Wu J; Xu A; Ahmeqd S; Sami A; Chibbar R; Freywald A; Zheng C; Xiang J
Vaccine; 2018 Mar; 36(11):1414-1422. PubMed ID: 29415817
[TBL] [Abstract][Full Text] [Related]
11. Targeting of the non-mutated tumor antigen HER2/neu to mature dendritic cells induces an integrated immune response that protects against breast cancer in mice.
Wang B; Zaidi N; He LZ; Zhang L; Kuroiwa JM; Keler T; Steinman RM
Breast Cancer Res; 2012 Mar; 14(2):R39. PubMed ID: 22397502
[TBL] [Abstract][Full Text] [Related]
12. Immunotargeting of the xCT Cystine/Glutamate Antiporter Potentiates the Efficacy of HER2-Targeted Immunotherapies in Breast Cancer.
Conti L; Bolli E; Di Lorenzo A; Franceschi V; Macchi F; Riccardo F; Ruiu R; Russo L; Quaglino E; Donofrio G; Cavallo F
Cancer Immunol Res; 2020 Aug; 8(8):1039-1053. PubMed ID: 32532810
[TBL] [Abstract][Full Text] [Related]
13. MEK inhibitors induce Akt activation and drug resistance by suppressing negative feedback ERK-mediated HER2 phosphorylation at Thr701.
Chen CH; Hsia TC; Yeh MH; Chen TW; Chen YJ; Chen JT; Wei YL; Tu CY; Huang WC
Mol Oncol; 2017 Sep; 11(9):1273-1287. PubMed ID: 28632938
[TBL] [Abstract][Full Text] [Related]
14. Enhancement of the p27Kip1-mediated antiproliferative effect of trastuzumab (Herceptin) on HER2-overexpressing tumor cells.
Marches R; Uhr JW
Int J Cancer; 2004 Nov; 112(3):492-501. PubMed ID: 15382077
[TBL] [Abstract][Full Text] [Related]
15. Sorafenib combined with HER-2 targeted vaccination can promote effective T cell immunity in vivo.
Sunay MM; Foote JB; Leatherman JM; Edwards JP; Armstrong TD; Nirschl CJ; Hicks J; Emens LA
Int Immunopharmacol; 2017 May; 46():112-123. PubMed ID: 28282575
[TBL] [Abstract][Full Text] [Related]
16. Exosomal pMHC-I complex targets T cell-based vaccine to directly stimulate CTL responses leading to antitumor immunity in transgenic FVBneuN and HLA-A2/HER2 mice and eradicating trastuzumab-resistant tumor in athymic nude mice.
Wang L; Xie Y; Ahmed KA; Ahmed S; Sami A; Chibbar R; Xu Q; Kane SE; Hao S; Mulligan SJ; Xiang J
Breast Cancer Res Treat; 2013 Jul; 140(2):273-84. PubMed ID: 23881522
[TBL] [Abstract][Full Text] [Related]
17. [Anti-HER2 vaccines: The HER2 immunotargeting future?].
Ladjemi MZ; Jacot W; Pèlegrin A; Navarro-Teulon I
Pathol Biol (Paris); 2011 Jun; 59(3):173-82. PubMed ID: 19481373
[TBL] [Abstract][Full Text] [Related]
18. Roles of human epidermal growth factor receptor 2, c-jun NH2-terminal kinase, phosphoinositide 3-kinase, and p70 S6 kinase pathways in regulation of cyclin G2 expression in human breast cancer cells.
Le XF; Arachchige-Don AS; Mao W; Horne MC; Bast RC
Mol Cancer Ther; 2007 Nov; 6(11):2843-57. PubMed ID: 18025271
[TBL] [Abstract][Full Text] [Related]
19. HER2-Positive Breast Cancer Immunotherapy: A Focus on Vaccine Development.
Arab A; Yazdian-Robati R; Behravan J
Arch Immunol Ther Exp (Warsz); 2020 Jan; 68(1):2. PubMed ID: 31915932
[TBL] [Abstract][Full Text] [Related]
20. Immunization with a HSP65-HER2 fusion peptide selectively eliminates HER2(+) B16 melanoma cells in a xenograft tumor mouse model.
Wang J; Wang X; Chen Y; Wan M; Xiang Z; Wu X; Wei H; Wang L; Zhang P; Wang L; Yu Y
Tumour Biol; 2013 Feb; 34(1):193-201. PubMed ID: 23055194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]